Eugene Mironets

Professional Background:

Eugene is an Associate Consultant with a background in neuroimmunology. Eugene is an expert in neurological disorders, including chronic degenerative disorders, and consequences resultant from neural injury (TBI, spinal cord injury). He supports a range of strategy and business development assignments, including market and pipeline opportunity assessments, R&D and preclinical strategy, and competitive landscape analyses.

Eugene received his PhD in Neuroscience in 2019 from Drexel University College of Medicine specializing traumatic spinal cord injury. He subsequently did his post-doctoral fellowship at the University of Pennsylvania investigating mechanisms by which viral infection and cannabinoids affect chronic degenerative CNS pathology. He has presented his work at several international conferences. Eugene has experience working with 2- and 3-dimensional human-induced pluripotent stem cell culture systems and has extensive knowledge of genetic engineering and DNA/RNA sequencing.

Recent Projects

Due Diligence

• For an academic research group, Eugene led a preclinical gap analysis for a neuros-scaffolding agent aimed at treating spinal cord injury.
• For a small pharmaceutical company looking to for a full due diligence assessment of small molecule inhibitor to treat chronic inflammatory diseases, Eugene led the organization of a comprehensive assessment of the competitive landscape, preclinical efficacy, clinical feasibility, and regulatory correspondence of the asset.

Technology Scouting:

• For a biotech company that was considering whether they should use a new gene editing technology for their disease target, Eugene supported the development of a profile of the technological and competitive landscape of modern gene editing and base editing.
• For a venture-backed, private biotech company, Eugene facilitated the investigation of a novel gene therapy aimed combatting age-related chronic disease. This involved assessment of the commercial attractiveness, feasibility, and therapeutic area prioritization of the gene therapy asset.
• For a public, mid-sized pharmaceutical company developing a small molecule therapy for treating iron metabolism symptoms of several diseases, Eugene led a new indication opportunity assessment to guide the selection of a new therapeutic area by the executive team. The assessment included an analysis of the competitive market, regulatory path, commercial attractiveness, technical feasibility, and market opportunity.

Education:

• September 2014 – April 2019: Drexel University College of Medicine, Ph.D. in Neuroscience
• September 2009 – May 2013: University of Connecticut, B.S. in Biology

Publications:

• Starr A, Jordan-Sciutto KL, Mironets E (2021). Confound, Cause, or Cure: The effect of cannabinoids on HIV-associated neurological sequelae. Viruses (in press)
• Ryan SK, Gonzalez MV, Garifallou JP, Bennett FC, Williams KS, Sotuyo NP, Mironets E, Cook K, Hakonarson H, Anderson SA, Jordan-Sciutto KL (2020). Neuroinflammation and EIF2 signaling persist despite antiretroviral treatment in an hiPSC tri-culture model of HIV infection. Stem Cell Reports. 14(5):991
• Hou S, Saltos TM, Mironets E, Trueblood CT, Connors TM, Tom VJ (2020). Grafting embryonic raphe neurons reestablishes serotonergic regulation of sympathetic activity to improve cardiovascular function after spinal cord injury. Journal of Neuroscience. 41:1654-19
• Mironets E, Fischer R, Bracchi-Ricard V, Saltos TM, Truglio TS, O’Reilly ML, Swanson KA, Bethea JR, Tom VJ (2020). Attenuating neurogenic sympathetic hyperreflexia improves immunity after chronic spinal cord injury. Journal of Neuroscience. 40(2):478-492.
• Mironets E, Osei-Owusu P, Bracchi-Ricard V, Fischer R, Owens EA, Ricard J, Wu D, Saltos TM, Collyer E, Hou S, Bethea JR, Tom VJ (2018). Inhibiting soluble TNFα mitigates autonomic dysreflexia and ensuing vascular and immune dysfunction after spinal cord injury. Journal of Neuroscience. 38(17):4146-4162.
• Mironets E, Wu D, Tom VJ (2016). Manipulating extrinsic and intrinsic obstacles to axonal regeneration after spinal cord injury. Neural Regeneration Research. 11(2):224-225.
• Partida E, Mironets E, Hou S, Tom VJ (2016). Cardiovascular dysfunction following spinal cord injury. Neural Regeneration Research. 11(1): 189-194.